Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT

@article{Rowe2015ImagingOM,
  title={Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT},
  author={Steven P. Rowe and Michael A. Gorin and Hans J. Hammers and M. Som Javadi and Hazem Hawasli and Zsolt Szab{\'o} and Steve Y. Cho and Martin G. Pomper and Mohamad E. Allaf},
  journal={Annals of Nuclear Medicine},
  year={2015},
  volume={29},
  pages={877-882}
}
  • Steven P. Rowe, Michael A. Gorin, +6 authors Mohamad E. Allaf
  • Published in Annals of Nuclear Medicine 2015
  • Medicine
  • ObjectiveMolecular imaging with positron emission tomography (PET) provides a powerful means of identifying and characterizing cancerous processes, as well as providing a quantitative framework within which response to therapy can be ascertained. Unfortunately, the most commonly used PET radiotracer, 18F-fluorodeoxyglucose (FDG), has not demonstrated a definitive role in determining response to therapy in metastatic renal cell carcinoma (RCC). As a result, new radiotracers able to reliably… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 46 CITATIONS

    PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art

    VIEW 8 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

    VIEW 12 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 12 REFERENCES

    68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma

    VIEW 1 EXCERPT

    Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma

    VIEW 1 EXCERPT

    2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

    VIEW 1 EXCERPT

    From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

    VIEW 1 EXCERPT